The RSM has an extensive digital learning and online e-resources platform. As a member you'll enjoy free access to a wealth of online resources, including 5,000 subscription and open access e-journals, 2,000 e-books and 5 key medical databases, to support your clinical decision-making and research.
- Date and time Mon 6 Jul 2020 from 10:00am to 3:30pm
- Location Live stream - online
- Organised by Medicine and Me
Please note: This is a live stream.
Please note: This event has been postponed and is now planned to take place in 2021. This page will be updated as soon as we have more details, and we will also contact booked delegates directly with this information. We apologise for any inconvenience this may have caused.
Jointly organised with Action for Pulmonary Fibrosis, this meeting will give you an understanding of what it is like to live with Idiopathic Pulmonary Fibrosis (IPF) from people living with the disease.
Pulmonary fibrosis (PF) is thought to affect around 70,000 people in the UK. One of the most aggressive and common forms of PF is Idiopathic Pulmonary Fibrosis (IPF). Idiopathic means it has no known cause. IPF normally affects people over 50 and is slightly more common in men than women. There are limited treatments and there is no cure. Life expectancy can be between three to five years following diagnosis, and around 6,000 people die from it every year in the UK.
Learn more about current approaches to diagnosis, treatment and management of IPF from the perspective of patients, their carers and clinicians, as well as gaining an insight into the psychological and emotional wellbeing of those living with IPF. We'll also explore the cutting edge research into improving outcomes and palliation, as we consider areas of inquiry likely to deliver step changes in treatments.
What will you learn?
By attending this meeting, you will have the opportunity to:
- Understand the most effective approaches to the diagnosis of IPF and the contribution of high-resolution imaging
- Know about the pharmacology and use of current anti-fibrotic drugs and the underlying biology that may lead to new approaches to treatments
- Understand the development of biomarkers, breath markers and other approaches to determining who is likely to respond to treatments
- Know from patients’ perspectives about the importance of palliative options and support for symptoms including breathlessness and mental health concerns
- Consider inequalities in access to management options, for example, care by specialist nurses
- Consider likely avenues for ”step changes” in treating IPF
About Medicine and Me
Medicine and Me meetings aim to provide an outline of current best practice and future updates of important conditions and to give direct voice to patients and their carers and enable them to discuss their concerns and reflections on the impact of diagnosis, investigation and management. Physicians and surgeons and indeed all healthcare professionals continue to learn from and be inspired to greater efforts to improve care by hearing directly from patients.
Join in the conversation online
Follow us on Twitter: @RoySocMed
We would like to thank our sponsors(s):
Galecto Biotech AB
Please note that none of the companies listed have had any influence or involvement over the agenda, content or organisation of this meeting.